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Abstract
 
Receptors for immunoglobulin (Ig)G (Fc
 
g
 
Rs) are important for the antibody-mediated effec-
tor functions of the immune system. Fc
 
g
 
RI and Fc
 
g
 
RIII trigger cell activation through a com-
mon 
 
g
 
 chain, whereas Fc
 
g
 
RII acts as a negative regulator of antibody production and immune
complex–triggered activation. Here we describe the in vivo consequences of Fc
 
g
 
R deficiency
in a mouse model of human rheumatoid arthritis. FcR
 
g
 
 chain–deficient mice on arthritis-sus-
ceptible DBA/1 background were immunized with collagen for induction of collagen-induced
arthritis. The DBA/1 mice lacking FcR
 
g
 
 chain were protected from collagen-induced arthritis
in contrast to wild-type mice, although both groups produced similar levels of IgG anticollagen
antibodies. In comparison, DBA/1 mice lacking Fc
 
g
 
RII developed an augmented IgG anticol-
lagen response and arthritis. These observations suggest a crucial role of Fc
 
g
 
RI and Fc
 
g
 
RIII in
triggering autoimmune arthritis.
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Introduction
 
IgG immune complexes (ICs) are of central importance in
the humoral immune system and are strongly implicated in
promoting inflammation and autoimmune diseases. Part of
the inflammatory response is attributed to the binding of
ICs to Fc receptors for IgG (Fc
 
g
 
Rs) on leukocytes. By
cross-linking Fc
 
g
 
Rs, a variety of cellular responses are trig-
gered including phagocytosis, antibody-dependent cellular
cytotoxicity, release of inflammatory mediators, IC clear-
ance, and regulation of antibody production. In this way,
Fc
 
g
 
Rs form a molecular link between the humoral and
cellular branches of the immune system. In the mouse,
there are three types of Fc
 
g
 
 receptors, the high-affinity re-
ceptor Fc
 
g
 
RI, capable of binding monomeric IgG, and the
two low-affinity receptors Fc
 
g
 
RII and Fc
 
g
 
RIII, which
bind IgG in the form of ICs. Both Fc
 
g
 
RI and Fc
 
g
 
RIII are
multimeric, whereas Fc
 
g
 
RII is a single chain receptor. Fc-
 
g
 
RI and Fc
 
g
 
RIII trigger cell activation through a common
 
g
 
 chain that contains an immunoreceptor tyrosine-based
activation motif (ITAM). In contrast, Fc
 
g
 
RII contains an
immunoreceptor tyrosine-based inhibitory motif (ITIM)
that via cocross-linking inhibits activation signals through
receptors containing ITAMs (for a review, see reference 1).
The specific contribution of each of the Fc
 
g
 
R classes to
normal and pathological immune responses is still not fully
 
understood. Mice deficient in the 
 
g
 
 subunit (FcR
 
g
 
2/2
 
) are
unable to phagocytose IgG-opsonized particles or to medi-
ate antibody-dependent cytotoxicity by NK cells (2) and
respond very poorly to IC-mediated enhancement of anti-
body responses (3). Furthermore, FcR
 
g
 
2/2
 
 mice show a
grossly diminished Arthus reaction (4) and are resistant to
autoantibody-dependent experimental hemolytic anemia,
thrombocytopenia, and glomerulonephritis (5, 6). These
results suggest that a wide range of inflammatory and au-
toimmune diseases may be mediated by Fc
 
g
 
Rs and not, as
previously thought, primarily by complement factors (for a
review, see reference 7). In contrast, targeted disruption of
Fc
 
g
 
RII in the mouse results in elevated Ig levels in re-
sponse to antigen challenge, augmented IgG-mediated ana-
phylaxis, and IC-mediated alveolitis (3, 8, 9), indicating
that Fc
 
g
 
RII acts as a negative regulator of antibody re-
sponses and IC-triggered activation.
 
Collagen-induced arthritis (CIA), a model of rheuma-
toid arthritis (RA), is induced in certain susceptible strains
of mice with injection of collagen type II (CII) in CFA
 
(10). This gives rise to a polyarthritis, characterized by syno-
vial hyperplasia, infiltration of mononuclear cells, pannus
formation, and destruction of cartilage and bone (11). It
has been previously well documented that antibodies to
CII are a prerequisite for CIA. B cell-deficient mice do not
develop arthritis (12), and arthritis can be transferred with
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hyperimmune anti-CII serum concentrate (13) or poly-
clonal IgG anti-CII antibodies (14, 15). Moreover, strain
susceptibility to CIA correlates well with high antibody re-
sponders to CII (11) and high levels of IgG anti-CII anti-
bodies. B cells producing IgG anti-CII have been found in
several RA patients (16, 17) as well, where presence of se-
rum IgG anti-CII early in disease is predictive of rapidly
progressive RA (18). However, the effector mechanism by
which antibodies contribute to arthritis development has
not been well understood. In the last few years, Fc recep-
tors have been proposed as candidate molecules for induc-
tion of inflammation, and in a recent report, we showed
that CIA is suppressed in mice lacking the low-affinity
receptor for IgE, Fc
 
e
 
RII (CD23) (19). It has also been
shown that deletion of Fc
 
g
 
RII can render arthritis-resis-
tant 129/SvJ and C57BL/6 hybrid mice susceptible to
CIA (20).
In this study, we have investigated the role of Fc
 
g
 
Rs in
CIA by studying FcR
 
g
 
 chain–deficient mice on arthritis-
susceptible DBA/1 background. We show here that mice
lacking the FcR
 
g
 
 chain are almost completely resistant to
CIA, although they develop similar immune reactivity to
CII as wild-type mice. In contrast, DBA/1 mice lacking
Fc
 
g
 
RII develop an augmented CIA with elevated serum
IgG anti-CII antibodies.
 
Materials and Methods
 
Mice.
 
FcR
 
g
 
 chain–deficient mice (2) and Fc
 
g
 
RII-deficient
mice (8) were backcrossed into DBA/1 background (H-2q)
(Bomholtgaard Ltd.) for five generations. The backcrossed mice
were then intercrossed to generate mice homozygous for the dis-
rupted FcR
 
g
 
 chain allele (FcR
 
g
 
2/2
 
) or the disrupted Fc
 
g
 
RII al-
lele (Fc
 
g
 
RII
 
2/2
 
). Littermates homozygous for the wild-type
FcR
 
g
 
 chain allele (FcR
 
g
 
1/1
 
) or the Fc
 
g
 
RII allele (Fc
 
g
 
RII
 
1/1
 
)
were used as controls. The FcR
 
g
 
 chain and the Fc
 
g
 
RII geno-
types were determined by PCR performed on isolated tail DNA.
PCR for the FcR
 
g
 
 genotype was carried out using primer sets
described elsewhere (2), and for the Fc
 
g
 
RII genotype three dif-
ferent primers were used: Neo (5
 
9
 
-CTG GTG CTT TAC GGT
ATC GCC-3
 
9
 
), 5
 
9
 
EC1 (5
 
9
 
-AAA CTC GAC CCC CCG TGG
ATC-3
 
9
 
), and 3
 
9
 
EC1 (5
 
9
 
-TTG ACT GTG TTA AAC GTG
TAG-3
 
9
 
). PCR was performed in 20-
 
m
 
l volumes using 10 mM
Tris-HCl, pH 8.3, 50 mM KCl, 4.4 mM MgCl
 
2
 
, 0.2 mM
dNTPs, 0.22 
 
m
 
M of primers, and 1 U of AmpliTaq DNA poly-
merase (Perkin-Elmer Cetus) for 35 cycles.
All mice were backcrossed, bred, and maintained at the Animal
Units of the Biomedical Centre and at the Unit of Pathology,
Uppsala University. The animals were fed rodent chow and water
ad libitum. Experiments were performed in age-matched mutant
and wild-type male mice.
 
Collagen Preparation.
 
Bovine type II collagen (BCII) was pre-
pared from nasal cartilage by pepsin digestion and subsequent pu-
rification as described previously (21). BCII was solubilized to a
concentration of 2 mg/ml in 0.01 M acetic acid (HAc) at 4
 
8
 
C
with constant mixing overnight.
 
Induction of CIA.
 
For induction of CIA, BCII was emulsified
with an equal volume (1:1) of CFA (Difco), and 50 
 
m
 
l of the
emulsion was injected intradermally, under light ether anesthesia,
at the base of the tail of each mouse.
 
Arthritis development was assessed by inspection three times a
week. Clinical severity of arthritis was quantified according to a
graded scale from 0 to 3 as follows: 0, normal; 1, detectable swell-
ing in one joint; 2, swelling in more than one but not in all joints;
and 3, severe swelling of the entire paw and/or ankylosis. Each
paw was graded, and each mouse could achieve a maximum score
of 12. A mean arthritic score value among only arthritic mice was
calculated.
 
Histologic Assessment of CIA.
 
At termination of the experi-
ments, the hind paws of four FcR
 
g
 
1/1
 
 and four FcR
 
g
 
2/2
 
 mice
were removed. The paws were fixed in phosphate buffer contain-
ing 4% formaldehyde, decalcified in EDTA, and paraffin embed-
ded as described previously (22). Sagital sections (5 
 
m
 
m) were
stained with hematoxylin and eosin and evaluated “blindly”
(without knowledge of the treatment groups).
 
Measurement of Anti-CII Antibodies.
 
Mice were bled from the
tails at different time points after immunization, and individual
sera were analyzed for CII-specific IgG antibodies by ELISA. Mi-
crotiter plates (Immunolon 2; Dynex Technologies) were coated
overnight at 4
 
8
 
C with 50 
 
m
 
l of native BCII in PBS at 200 
 
m
 
g/ml.
Plates were washed with PBS containing 0.05% Tween 20 (PBS/
Tween), and serum samples were added in serial dilution with
PBS/Tween and incubated for 2 h at room temperature (rt). The
plates were then washed and incubated for 2 h at rt with 50 
 
m
 
l of
sheep anti–mouse IgG conjugated to alkaline phosphatase (Jackson
ImmunoResearch Laboratories) diluted 1:1,000 in PBS/Tween.
After additional washings, 50 
 
m
 
l of 
 
p
 
-nitrophenyl phosphate sub-
strate (Sigma Chemical Co.) diluted in diethanolamine buffer at 1
mg/ml was applied. Absorbances were read after 20 min at 405
nm. A polyclonal anti-BCII standard with known concentration
was included on every microtiter plate to allow calculation of the
antibody content by using Softmax software (Molecular Devices).
The standard was purified by affinity chromatography from pooled
sera obtained from BCII hyperimmunized mice.
ELISA to detect CII-specific IgG isotypes was performed with
a modified protocol of the assay described above. After incubation
of serum samples overnight at 4
 
8
 
C, 50 
 
m
 
l of biotinylated rat anti–
mouse IgG1 (diluted 1:2,000), IgG2a (diluted 1:10,000), IgG2b
(diluted 1:10,000), or IgG3 (diluted 1:5,000) (all from Southern
Biotechnology Associates, Inc.) was applied to the plates for 5 h at
rt. After washings 50 
 
m
 
l of streptavidin–alkaline phosphatase (di-
luted 1:1,000; Serotec) was added and incubated for 1 h at rt. The
plates were washed and 
 
p
 
-nitrophenyl phosphate substrate was
added. The concentration of antibodies was calculated by compar-
ison with the polyclonal anti-BCII standard.
 
Proliferation Assay.
 
FcR
 
g
 
2/2
 
 and FcR
 
g
 
1/1
 
 mice were killed
14 d after BCII/CFA immunization and inguinal, popliteal, and
axillary LNs were removed. Individual single cell suspensions
were made in DMEM supplemented with 2-ME (50 
 
m
 
M), Hepes
(10 mM), glutamine (20 mM), penicillin (100 U/ml), streptomy-
cin (100 
 
m
 
g/ml), and 5% FCS. The LN cells (LNCs, 5 
 
3
 
 10
 
5
 
)
were plated in 96-well round-bottomed microtiter plates and
stimulated in triplicate in the absence or presence of 5, 50, or 100
 
m
 
g/ml of heat-denatured BCII (dCII) in 0.01 M HAc. The cells
were incubated at 37
 
8
 
C in 5% CO
 
2
 
 for 4 d, and 1 
 
m
 
Ci/well of
[
 
3
 
H]TdR was added to the culture for the last 18 h. [
 
3
 
H]TdR in-
corporation was measured using a 
 
b
 
-scintillation counter, and the
results were expressed as the mean cpm 
 
6 
 
SD of the LNC prepa-
rations derived from four FcR
 
g
 
2/2
 
 or four FcR
 
g
 
1/1
 
 mice.
 
Statistics.
 
The severity of arthritis was analyzed using the
Mann-Whitney U-test and the frequency of arthritis by Fisher’s
exact test. The antibody levels and proliferation assay were ana-
lyzed with Student’s 
 
t
 
 test. 
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Results
DBA/1 Mice Lacking FcRg Chain Are Highly Protected from
CIA. To investigate the involvement of the FcgRs in the
development of CIA, FcRg chain–deficient mice and their
littermate controls, each on DBA/1 background, were im-
munized with CII. Clinical arthritis was observed in
FcRg1/1 mice from day 21 onward (Fig. 1, A and B). The
disease progressed to severe arthritis, and by the termina-
tion of the experiment 80% of the FcRg1/1 mice were ar-
thritic (Fig. 1 A) with a mean arthritic score of 7 (Fig. 1 B).
In contrast, only one FcRg2/2 mouse developed clinical
signs of arthritis within the first few weeks after immuniza-
tion (Fig. 1, A and B). This mouse had swelling in a single
digit that went into spontaneous remission after 10 d.
Around days 50 and 70 after immunization, another two
FcRg2/2 mice developed mild arthritis (Fig. 1, A and B).
The arthritis manifestations in these mice were similar to
the previously arthritic FcRg2/2 mouse, with clinical ar-
thritis restricted to the swelling of only a single digit. To
confirm the clinical assessments, at killing the clinically pos-
itive hind paws of the two responding FcRg2/2 mice as
well as hind limbs of two nonarthritic FcRg2/2 mice and
those of four clinically positive FcRg1/1 mice were sub-
jected to histopathology. Arthritis in wild-type mice in-
cluded synovial hyperplasia, increased vascularization, and
extensive infiltration of periarticular tissue by mononuclear
cells and granulocytes. Frequently seen was pannus forma-
tion and severe erosion of cartilage and bone (Fig. 2 A). By
comparison, the joints of the two FcRg2/2 mice that de-
veloped arthritis exhibited synovial hyperplasia and synovial
villi formation (Fig. 2 B), whereas inflammatory cell infil-
trates and erosions of cartilage and bone were absent. Joints
of nonarthritic FcRg2/2 mice showed no pathological
changes. The synovial tissue was normal, and cartilage and
underlying bone were intact (Fig. 2 C).
The Anti-CII Response Is Not Altered in FcRg2/2 Mice.
To investigate if the immune response against CII was dif-
ferent in FcRg2/2 compared with FcRg1/1 mice, we ana-
lyzed cellular and humoral immunity to CII. BCII-primed
Figure 1. Protection from
CIA in FcRg-deficient DBA/1
mice. CII-immunized FcRg1/1
mice (filled symbols, n 5 20) and
FcRg2/2 mice (open symbols,
n  5  18) were observed for arthritic
lesions, and the percentage of
mice that developed disease (A)
and the mean severity of arthritis
in diseased animals (B) are
shown. The figure shows results
from one representative experi-
ment out of two performed.
Figure 2. Histopathology of tarsal joints from FcRg1/1 and FcRg2/2
DBA/1 mice 80 d after CII immunization. Severe arthritis was seen in
FcRg1/1 mice (A) with inflammatory cellular infiltrate, invasive pannus,
and erosions of cartilage and bone clearly detectable. The few FcRg2/2
mice that developed disease (B) showed proliferation of synovial lining
layer, synovial villi formation, but absence of cellular infiltrate and ero-
sions. Joints of nonaffected FcRg2/2 mice (C) were normal in appear-
ance, with normal synovia and smooth intact cartilage. Representative
sagittal paraffin sections with hematoxylin-eosin stain; original magnifica-
tions: (A) 320; (B and C) 350.
LNCs from FcRg2/2 and FcRg1/1 mice had a low prolif-
erative response to antigenic stimulation with dCII (Fig. 3).
No significant differences of the CII-specific proliferation
were found between the groups.
In sera taken from mice periodically during the experi-
ment, it was shown that the total IgG anti-CII levels did
not differ between FcRg2/2 and FcRg1/1 mice (Fig. 4 A).
However, FcRg2/2 mice developed significantly higher
IgG1 anti-CII levels at all time points, whereas IgG2a,
IgG2b, and IgG3 levels were not significantly different be-
tween the two groups (Fig. 4 B).
Augmented CIA in DBA/1 Mice Lacking FcgRII. In two
independent experiments, FcgRII2/2 mice on DBA/11614 Protection from CIA in FcRg-deficient Mice
background proved to be more susceptible for induction of
arthritis than FcgRII1/1 littermates. As early as 30 d after
immunization, 75% of the FcgRII2/2 mice had developed
arthritis, whereas only 8% of the FcgRII1/1 mice were ar-
thritic (P , 0.01; Fig. 5 A). The FcgRII2/2 mice devel-
oped not only a more rapidly progressing arthritis, but also
a clinically more severe disease; by day 42 after immuniza-
tion, FcgRII2/2 mice exhibited a mean clinical score of
9.36 6 3.0 in contrast to 3.7 6 2.3 in FcgRII1/1 mice (P ,
0.05; Fig. 5 B). Furthermore, the FcgRII2/2 mice devel-
oped very high serum IgG anti-CII levels; at 5 wk, a mean
of 4.75 mg/ml total IgG anti-CII was found in the FgRII-
deficient mice compared with 0.82 mg/ml in the FgRII1/1
mice (Fig. 6 A). The CII-specific antibody response in the
FcgRII2/2 mice was not restricted to a particular subclass:
all subclasses were significantly increased at 3 and 5 wk after
immunization compared with FcgRII1/1 mice (Fig. 6 B).
Discussion
The CIA model has been shown to be dependent on B
cells (12), promoting the important IgG anti-CII response.
Thus, high amounts of IgG anti-CII antibodies have
proven to be pathogenic when transferred to naive recipi-
ents (14, 15). Here we show that mice lacking the FcRg
chain are almost completely resistant to CIA, although
equal levels of IgG anti-CII antibodies were demonstrated
in FcRg2/2 mice as in wild-type mice during the course of
the experiment. The proliferative response to CII in
FcRg2/2 mice was similar to that in wild-type animals,
suggesting that the T and B cell compartments function
normally in FcRg2/2 mice. Absence of arthritis in spite of
this indicates that the FcRg chain is linked to a crucial
“downstream” effector arm in the development of arthritis.
As IgG antibodies are important for this process, as also
shown in other arthritis models (23), the most likely recep-
tors implicated are FcgRI and/or FcgRIII, both shown to
be functionally impaired in FcRg2/2 animals (2). How-
ever, the definite identity of the receptor(s) involved can-
not be established until mouse strains selectively lacking the
various FcRg chain–associated receptors are available on an
arthritis-susceptible background. Previous reports have
shown that inflammation triggered by ICs depends prima-
rily on engagement and activation of g chain–associated Fc
receptors (4–6). This study adds to this, also highlighting
Figure 3. Proliferation of CII-
primed LNCs in response to CII.
LNCs from BCII-immunized
FcRg1/1 (black bars, n 5 4) and
FcRg2/2 mice (hatched bars, n 5
4) were stimulated in vitro with
different antigen doses of heat-
denatured CII (dCII). Prolifera-
tive responses were determined
after 4 d of culturing by uptake
of [3H]TdR. No significant dif-
ference between the groups was
found.
Figure 4. Anti-CII antibod-
ies in FcRg-deficient DBA/1
mice.  Circulating CII-specific
antibodies were determined pe-
riodically after BCII immuniza-
tion in individual sera of FcRg1/1
(filled symbols) and FcRg2/2
mice (open symbols). The mean 6
SD antibody levels of total IgG
anti-CII (A) and subclass-specific
IgG anti-CII (B) are shown. *P ,
0.05 compared with the FcRg1/1
group.
Figure 5. Augmented CIA in
FcgRII-deficient DBA/1 mice.
CII-immunized FcgRII1/1
(filled symbols, n 5 12) and
FcgRII2/2 mice (open symbols,
n 5 12) were observed for ar-
thritic lesions, and the percentage
of mice that developed disease
(A) and the mean severity of ar-
thritis in diseased animals (B) are
depicted. The figure shows re-
sults from one representative ex-
periment out of two performed.
Figure 6. Anti-CII antibodies
in FcgRII-deficient DBA/1
mice.  Circulating CII-specific
antibodies were determined peri-
odically after BCII immunization
in individual sera of FcgRII1/1
(filled symbols) and FcgRII2/2
mice (open symbols). The mean 6
SD antibody levels of total IgG
anti-CII (A) and subclass-spe-
cific IgG anti-CII (B) are shown.
*P  ,  0.05,  **P  ,  0.01, and
***P  ,  0.001 compared with the
FcgRII1/1 group.1615 Kleinau et al. Brief Definitive Report
the absolute requirement for g chain activation in the com-
plex autoimmune disease model, CIA. In addition, our re-
sults show that neither FcgRII nor the complement sys-
tem, both present in the FcRg2/2 animals, are sufficient to
trigger CIA.
There are several, not mutually exclusive, effector path-
ways that could be used by the FcRg chain in the develop-
ment of arthritis. FcRg chain–containing receptors were
recently shown to play a crucial role for the ability of ICs
to trigger strong antibody responses in vivo (3). This en-
hancement of antibody responses by ICs may be operative
in the early phases of CIA, resulting in accumulation of
IgG autoantibodies that may precipitate and bind to joint
constituents. Uptake by resident FcgRIII and/or FcgRI
inflammatory cells may trigger inflammation and recruit-
ment of circulating monocytes and neutrophils. In fact, the
lack of infiltrating leukocytes in the synovium of FcRg2/2
mice could be linked to a decreased chemotactic activity in
the joints due to FcgRIII deficiency. Cross-linking of Fc-
gRIII on human monocytes from peripheral blood with
immobilized IgG induces monocyte chemoattractant pro-
tein 1 (24), a chemokine also detected in joints of RA pa-
tients (25).
In this study, we find diverse susceptibility to CIA by
studying two different FcgR-deficient strains on the arthri-
tis-susceptible DBA/1 background. Thus, DBA/1 mice
lacking FcgRII developed a clinically more severe arthritis
with an earlier onset than wild-type mice. We propose that
these divergent results are due to the fact that FcRg2/2
mice lack FcgRI and FcgRIII, whereas in FcgRII2/2 mice
these FcgRs are present. FcgRII has been shown to func-
tion as a negative regulator of antibody production and IC-
triggered activation, where mice lacking FcgRII show a
greatly enhanced IgG-mediated passive cutaneous anaphy-
lactic response (8). FcgRII has also been demonstrated to
have an inhibitory role on macrophages by regulating phago-
cytic and calcium flux responses (9). Thus, we interpret
the augmented CIA in FcgRII2/2 mice as a result of ele-
vated antibody levels and an amplified effector response to
ICs. The increased susceptibility of arthritis in FcgRII2/2
DBA/1 mice compared with FcgRII1/1 mice is in line
with a previous finding where a CIA-resistant mouse strain
carrying the H-2b haplotype was rendered susceptible to
CIA through deletion of FcgRII (20).
Our findings clearly demonstrate the important role of
distinct FcgRs for induction and suppression of arthritis.
IgG-triggered activation of the ITAM-associated FcgRI
and FcgRIII are crucial for arthritis development, whereas
ITIM-associated FcgRII downregulates autoimmune re-
sponses and arthritis. The balance of FcRg-stimulatory and
FcgRII-inhibitory signals will most likely determine the
threshold of IC stimulation and the outcome of arthritis af-
ter immunization with CII in a potent adjuvant. Depend-
ing on which receptors are available for ligation, disease can
either be completely prevented or dramatically enhanced.
The data presented suggest that a future possibility for
treating RA could be to find ways to specifically inhibit
signaling through the FcRg chain.
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